Antibodies Causing Epilepsy Syndromes: The ACES Study.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

582 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Antibodies Causing Epilepsy Syndromes (ACES) Study is a observational cohort study focusing on detection of auto-immune epilepsy in patients with epilepsy of unknown origin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients

NCT00394927

Epilepsy

COMPLETED

Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy

NCT05422664

Autoimmune Encephalitis Epilepsy Seizures

ENROLLING_BY_INVITATION

Study of Predictors of Response to Anti Epilepsy in Epilepsy

NCT02883712

Seizure

TERMINATED

Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study

NCT00041951

Childhood Absence Epilepsy Epilepsy Seizures

COMPLETED

Biology of Juvenile Myoclonic Epilepsy

NCT03400371

Juvenile Myoclonic Epilepsy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recently new treatable causes of epilepsy have been identified. These disorders are caused by a disruption of the balance in the brain caused by inflammation. This inflammatory reaction is caused by an autologous reaction of the immune system to specific brain proteins. The body produces antibodies to specific parts of the brain. These disorders can lead to epilepsy, memory dysfunction and psychiatric problems. Recognition is necessary for good treatment. Mostly anti-epileptic drugs are insufficient. These diseases can be treated with immune-modulating therapy. The ACES Study will focus on determining the frequencies of known antibodies and finding new, currently unknown, antibodies, causing epilepsy. Therefore patients will be investigated with epilepsy of unknown origin. To find new antibodies sera of patients with epilepsy will be added to brain sections of rats and to cultivated neuronal cells to look for a reaction. If new antibodies will be detected clinical features will be mapped of the patients. Also effects of antibodies on brain cells will be determined. Discovery of new antibodies can provide new treatment options for these patients. Also it will enable to discover more about the pathologic mechanisms of epilepsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Auto-immune Encephalitis Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

acquired chronic, focal, epilepsy

patients ≥18 years of age, with acquired chronic epilepsy of unknown origin

vena punction

Intervention Type BIOLOGICAL

new onset epilepsy

patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis

vena punction

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vena punction

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of 18 and older.
* Status epilepticus or new onset seizures with signs of limbic encephalitis (clinical picture, MRI (FLAIR abnormalities), EEG abnormalities or CSF findings (CSF pleocytosis, increased IgG index, oligoclonal bands), or:
* Patients with acquired chronic focal epilepsy with an unknown cause.